T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Thomas Powles,Irfan Kayani,Christian U. Blank,Simon Chowdhury,Simon Horenblas,Naveed Sarwar,Paul Nathan,Ekaterini Boleti,John B. A. G. Haanen,Axel Bex +9 more
TL;DR: This interim analysis suggest nephrectomy after upfront pazopanib can be performed safely in mRCC and obtains control of disease in the majority of patients.
Journal ArticleDOI
Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.
TL;DR: In this paper, an overview of ongoing trials and early translational research outcomes of immunotherapy for non-metastatic renal cell carcinoma (RCC) is presented. But, the authors do not discuss the effect of delayed cytoreductive nephrectomy following pretreatment with ICI.
Journal ArticleDOI
Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).
Axel Bex,Yasmin Abu-Ghanem,Johannes V. van Thienen,Niels M. Graafland,Brunolf W. Lagerveld,Patricia J. Zondervan,H.P. Beerlage,R. Jeroen A. van Moorselaar,Mark M. Kockx,Peter van Dam,Bernadett Szabados,Christian U. Blank,Thomas Powles,John B. A. G. Haanen +13 more
TL;DR: Neoadjuvant avelumab/axitinib for non-metastatic high-risk RCC leads to PR of the PT in 30% which is associated with DFS and OS, and postoperative adverse events occurred in 8 pts (2 Clavien Dindo grade 3a).
Journal ArticleDOI
Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.
Nizar M. Tannir,Robert J. Motzer,Elizabeth R. Plimack,David F. McDermott,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,Christian Kollmannsberger,Howard Gurney,Asim Amin,Marc-Oliver Grimm,Brian I. Rini,Yoshihiko Tomita,M. Brent McHenry,Sabeen Mekan,Bernard Escudier,Hans J. Hammers +18 more
TL;DR: Discontinuation of first-line N+I due to TRAEs did not result in impaired outcomes, and a high proportion of pts remain alive and free from second-line therapy.
Journal ArticleDOI
The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β1 in metastatic human breast cancer: an immunocytochemical study
TL;DR: It is concluded that neither tamoxifen nor aromatase inhibitors produce a change in the ER content or TGF-beta 1 content of breast tumours as detected immunocytochemically, but PR levels are significantly reduced after therapy in responding patients.